Sutro Biopharma, Inc.

As of June 30, 2026, Sutro Biopharma, Inc. carries a market capitalization of 480.71M, placing it among publicly traded companies globally. Its enterprise value stands at 346.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sutro Biopharma, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Sutro Biopharma, Inc. has 16.58M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 8.47, and the price-to-book ratio stands at -5.32.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 346.30M versus a market cap of 480.71M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sutro Biopharma, Inc. maintains a current ratio of 3.32, meaning it holds 3.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -10.44, indicating conservative leverage, while an interest coverage ratio of -3.37 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -79.08, reflecting losses generated across the asset base. The company generates approximately 213,633.97 in revenue per employee across its workforce of 187.25, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Sutro Biopharma, Inc. recorded an income tax benefit of -84,028.80 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -158.19M and -158.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 14.74, while the 200-day moving average is 20.07.

Over the twelve months ended June 30, 2026, Sutro Biopharma, Inc. generated 40.00M in revenue and converted that into -158.11M in net income, yielding earnings per share of -13.54. EBITDA reached -122.53M, while operating income came in at -115.42M.

As of June 30, 2026, Sutro Biopharma, Inc. holds 143.85M in cash and equivalents against 9.44M in total debt, resulting in a net debt position of -47.56M. Total book value stands at -90.43M, with working capital of 107.44M providing operational flexibility.

Sutro Biopharma, Inc. produced -127.07M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -390,383.80 in capital expenditures, free cash flow totaled -127.46M - equivalent to -10.91 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -288.52 and net profit margin of -395.25 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -37.63: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -18.70, meaning Sutro Biopharma, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Sutro Biopharma, Inc.'s most recent stock split took place on December 3, 2025 with a 10:1 split ratio.

As of June 30, 2026, Sutro Biopharma, Inc. has an Altman Z-Score of -7.73, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.